目的对比并分析血必净单独及其联合胸腺五肽对重症肺炎患者的临床治疗效果。方法 153例重症肺炎患者,采用简单抽样法分成联合用药组(A组,n=76)和单一对照组(B组,n=77)。B组采用血必净进行治疗,A组在B组基础上应用胸腺五肽进行治疗,比对两组患者临床治疗效果及不良反应发生差异。结果 1治疗后,A组总有效率为97.4%,明显高于B组的77.9%,对比差异有统计学意义(P<0.05);2用药后,两组患者均无严重不良反应发生,其中A组出现恶心头晕、胸闷、无力等轻微不良反应者共14例,发生率为18.4%,同B组的20.1%(16/77),对比差异无统计学意义(P>0.05)。结论对重症肺炎患者予以血必净联合胸腺五肽方案,疗效确切,值得临床推广。 Objective To compare and analyze the clinical effects of Xuebijing alone and in combination with thymopentin on patients with severe pneumonia. Methods 153 patients with severe pneumonia were divided into the combination group (A group, n = 76) and the single control group (B group, n = 77) by simple sampling method. Group B was treated with Xuebijing, group A was treated with thymopentin on the basis of group B, and the differences between the two groups in clinical efficacy and adverse reactions were compared. Results 1 After treatment, the total effective rate of group A was 97.4%, which was significantly higher than that of group B (77.9%), the difference was statistically significant (P <0.05); 2 after treatment, no serious adverse reactions occurred in both groups, of which A group of nausea and dizziness, chest tightness, weakness and other minor adverse reactions were 14 cases, the incidence was 18.4%, with B group 20.1% (16/77), the difference was not statistically significant (P> 0.05). Conclusion Severe pneumonia patients given Xuebijing combined thymopentin program, the exact effect, is worthy of clinical promotion.